U.S. markets open in 9 hours 19 minutes
  • S&P Futures

    4,363.00
    +14.00 (+0.32%)
     
  • Dow Futures

    34,239.00
    +54.00 (+0.16%)
     
  • Nasdaq Futures

    14,231.75
    +91.00 (+0.64%)
     
  • Russell 2000 Futures

    2,003.00
    +1.70 (+0.08%)
     
  • Crude Oil

    85.24
    -0.36 (-0.42%)
     
  • Gold

    1,847.50
    -5.00 (-0.27%)
     
  • Silver

    23.78
    -0.11 (-0.46%)
     
  • EUR/USD

    1.1306
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.7830
    +0.0480 (+2.77%)
     
  • Vix

    31.16
    +1.26 (+4.21%)
     
  • GBP/USD

    1.3510
    +0.0004 (+0.03%)
     
  • USD/JPY

    113.8970
    +0.0310 (+0.03%)
     
  • BTC-USD

    37,708.62
    +1,621.52 (+4.49%)
     
  • CMC Crypto 200

    856.92
    +36.33 (+4.43%)
     
  • FTSE 100

    7,371.46
    +74.31 (+1.02%)
     
  • Nikkei 225

    27,079.97
    -51.37 (-0.19%)
     

SpringWorks Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • SWTX

STAMFORD, Conn., June 02, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020 at 8:50 a.m. Eastern Standard Time.

A video webcast will be available live on the “Events & Presentations” page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for approximately 30 days following the conference.

About SpringWorks Therapeutics
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with industry leaders to expand its portfolio. For more information, please visit www.springworkstx.com. Follow SpringWorks Therapeutics on social media: @SpringWorksTx and LinkedIn.

Contact:
Kim Diamond
Phone: 203-561-1646
Email: kdiamond@springworkstx.com